Correction to: Journal of Neurology 10.1007/s00415-018-8812-0
In the original article, the co-author’s family name has been published incorrectly. The correct family name should be Constantinescu.
Compliance with ethical standards
Ethical standards
This study has been approved by the local institutional review board and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Footnotes
The original article can be found online at 10.1007/s00415-018-8812-0.
References
- 1.Genzyme . Lemtrada [prescribing information] Cambridge: Genzyme Corporation; 2016. [Google Scholar]
- 2.Cohen JA, Coles AJ, Arnold DL, et al. CARE MS I Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–1828. doi: 10.1016/S0140-6736(12)61769-3. [DOI] [PubMed] [Google Scholar]
- 3.Coles AJ, Twyman CL, Arnold DL, et al. CARE MS II Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839. doi: 10.1016/S0140-6736(12)61768-1. [DOI] [PubMed] [Google Scholar]
- 4.Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89:1107–1116. doi: 10.1212/WNL.0000000000004313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Coles AJ, Cohen JA, Fox E, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89:1117–1126. doi: 10.1212/WNL.0000000000004354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Al-Sawaf O, Fischer K, Herling CD, et al. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur J Haematol. 2017;98:254–262. doi: 10.1111/ejh.12825. [DOI] [PubMed] [Google Scholar]
- 7.Osterborg A, Foa R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia. 2009;23:1980–1988. doi: 10.1038/leu.2009.146. [DOI] [PubMed] [Google Scholar]
- 8.Sylvan ES, Lundin J, Ipek M, et al. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients. Ann Hematol. 2014;83:1725–1733. doi: 10.1007/s00277-014-2105-1. [DOI] [PubMed] [Google Scholar]
- 9.Morgan RD, O’Callaghan JM, Knight SR, et al. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation. 2012;93:1179–1188. doi: 10.1097/TP.0b013e318257ad41. [DOI] [PubMed] [Google Scholar]
- 10.Van der Zwan M, Baan CC, Van Gelder T, et al. Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation. Clin Pharmacokinet. 2018;57:191–207. doi: 10.1007/s40262-017-0573-x. [DOI] [PMC free article] [PubMed] [Google Scholar]